Navigation Links
Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
Date:4/17/2008

a Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effe
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Three years ago, ... location for his Shore Vascular & Vein Center! ... circulatory system. It is his mission to provide the ... respect. , Dr. Jeffrey Gosin is Board Certified ... the University of Pennsylvania and Jefferson Medical College. He completed ...
(Date:5/28/2015)... Are policies that spell out when Medicare pays for ... for seniors? That’s what a study published this month ... figure out, and its findings could have implications due ... “Observation Encounters and Subsequent Nursing Facility Stays,” led ... policies that distinguish between an “inpatient” hospital stay and ...
(Date:5/28/2015)... 28, 2015 The Paw Project, ... a dramatic billboard intended to educate the Oregon public ... the busy intersection of Market Street and Park Avenue ... “If You’re for De-clawing Cats, Raise Your Hand,” depicts ... last joint, providing a graphic and anatomically-correct representation of ...
(Date:5/28/2015)... " Trends Investing ” was featured on NewsWatch ... look at small, medium, and large businesses making an impact ... business expert, conducted the business review and shared with viewers ... should invest their money. , The idea, “let your money ... it and knowing how to succeed are two different things. ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2
... important hormone necessary for statural growth and must be ... to grow normally. In healthy individuals, growth hormone is ... that binds to growth hormone receptors on liver and ... secretion of IGF-1 into the bloodstream., ,Any defect ...
... gathering for National Association of Neonatal Nurses Lead Media ... of preventing occurrence of RSV to premature babies. //, ... to 36 weeks gestation each year in the United ... weak immune systems leave these fragile patients susceptible to ...
... Clinic Molecular Immunologist and his team has found a new ... cancer, inflammation and autoimmune diseases. The new delivery system acts ... Therapeutic virus containing the required genes are transferred into the ... are the immune cells they get attracted towards the cancer ...
... people in the world after South Africa and now threats// ... to a World Economic Survey. ,The surveys message ... business due to AIDS in the next five years.", ... report some impact of the AIDS virus on ...
... Drug Azathioprine, which is used as an immunomodulating drug ... and autoimmune disorders is found to increase the incidence ... O’Donovan and colleagues from London Research Institute in Hertfordshire ... the patient taking the drug and when the skin ...
... of a recent study researchers say that certain chemicals found ... help current and former smokers ward off development of lung ... ,Researchers say their study provides significant insight into the ... the process can be slowed down after exposure has already ...
Cached Medicine News:Health News:Skin cancer linked to usage of Drug Azathioprine in organ transplants 2
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... SOUTH SAN FRANCISCO, Calif. , May 28, 2015 ... the treatment of cancer, today announced that Sean ... at the upcoming Jefferies 2015 Global Healthcare Conference ... 2:30 p.m. EDT on Tuesday, June 2, 2015. Dr. ... including the company,s Precision cancer immunotherapy and Probody drug ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... FRANCISCO, July 21, 2011 ClinStar, LLC , ... and Eastern Europe to the pharmaceutical and biotechnology industry, ... speak at Marcus Evans 6th Annual Clinical Research ... FL.    (Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO ) ...
... July 21, 2011 Endologix, Inc. (NASDAQ: ELGX ... today announced financial results for the three and six months ... and Chief Executive Officer, said, "We are pleased with our ... our growth and new product development goals for 2011.  In ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
SHERIDAN PREFORMED™ Endotracheal Tubes are designed to conveniently position the anesthesia circuit out of the surgical field for oral and maxillofacial procedures....
Nasal soft cuffed endotracheal tubes designed and constructed especially for long-term nasal intubations....
... is the next step in the ... is an easy to use, easy ... used as a standard tube, as ... quickly and safely handle intubations of ...
Medicine Products: